Identification and Characterization of a Highly Efficient Anti-HIV Pol Hammerhead Ribozyme

Oligonucleotides

Volumn 19, Issue 3, 2009, Pages 265-271

  Müller Kuller, Thea ^a   Capalbo, Gianni ^a   Klebba, Christian ^a   Engels, Joachim W ^a   Klein, Stefan A ^b  

^a GOETHE UNIVERSITY   (Germany)

^b INSTITUTE OF PATHOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; HAMMERHEAD RIBOZYME; HHPOL 13; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; PRIORITY JOURNAL; STRUCTURAL GENE; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE, TUMOR; GENETIC VECTORS; HIV-1; HUMANS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, CATALYTIC; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70349288033     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2008.0150     Document Type: Article

References (23)

1. ANDERSON, J., LI, M.J., PALMER, B., REMLING, L., LI, S., YAM, P., YEE, J.K., ROSSI, J., ZAIA, J., and AKKINA, R. (2007). Safety and eff cacy of a lentiviral vector containing three anti-HIV genes CCR5 ribozyme, tat-rev siRNA, and TAR decoy in SCID-hu mouse-derived T cells. Mol. Ther. 15, 1182-1188.
2. CASTANOTTO, D., and ROSSI, J.J. (2009). The promises and pitfalls of RNA-interference-based therapeutics. Nature. 457, 426-433.
3. DIANZANI, F., CAPOBIANCHI, M.R., ANTONELLI, G., AMICUCCI, P., and DE MARCO, F. (1989). Susceptibility of human immuno-def ciency virus to antiviral agents measured by infectious virus yield reduction. Antiviral Res. 11, 299-305.
4. FEDOR, M.J. (2004). Determination of kinetic parameters for hammerhead and hairpin ribozymes. Methods Mol. Biol. 252, 19-32.
5. HENDRY, P., MCCALL, M.J., and LOCKETT, T.J. (1997). Characterizing ribozyme cleavage reactions. Methods Mol. Biol. 74, 221-229.
6. KLEBBA, C., OTTMANN, O.G., SCHERR, M., PAPE, M., ENGELS, J.W., GREZ, M., HOELZER, D., and KLEIN, S.A. (2000). Retrovirally expressed anti-HIV ribozymes confer a selective survival advantage on CD4+ T cells in vitro. Gene Ther. 7, 408-416
7. LARSSON, S., HOTCHKISS, G., SU, J., KEBEDE, T., ANDANG, M., NYHOLM, T., JOHANSSON, B., SONNERBORG, A., VAHLNE, A., BRITTON, S., and AHRLUND-RICHTER, L. (1996). A novel ribozyme target site located in the HIV-1 nef open reading frame. Virology. 219, 161-169.
8. LI, M.J., KIM, J., LI, S., ZAIA, J., YEE, J.K., ANDERSON, J., AKKINA, R., and ROSSI, J.J. (2005). Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 12, 900-909.
9. LI, M., LI, H., and ROSSI, J.J. (2006). RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann. N. Y. Acad. Sci. 1082, 172-179.
10. OJWANG, J.O., HAMPEL, A., LOONEY, D.J., WONG-STAAL, F., and RAPPAPORT, J. (1992). Inhibition of human immunodef ciency virus type 1 expression by a hairpin ribozyme. Proc. Natl. Acad. Sci. USA 89, 10802-10806.
11. PARK, W.S., HAYAFUNE, M., MIYANO-KUROSAKI, N., and TAKAKU, H. (2003). Specif c HIV-1 env gene silencing by small interfering RNAs in human peripheral blood mononuclear cells. Gene Ther. 10, 2046-2050.
12. PEAR, W.S., NOLAN, G.P., SCOTT, M.L., and BALTIMORE, D. (1993). Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA. 90, 8392-8396.
13. ROSSI, C., BALBONI, P.G., BETTI, M., MARCONI, P.C., BOZZINI, R., GROSSI, M.P., BARBANTI-BRODANO, G., and CAPUTO, A. (1997). Inhibition of HIV-1 replication by a Tat transdomi-nant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients. Gene Ther. 4, 1261-1269.
14. ROSSI, J.J. (1999). The application of ribozymes to HIV infection. Curr. Opin. Mol. Ther. 1, 316-322.
15. ROSSI, J.J. (2000). Ribozyme therapy for HIV infection. Adv. Drug D e l i v. R e v. 44, 71-78.
16. SCHERER, L., ROSSI, J.J., and WEINBERG, M.S. (2007). Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther. 14, 1057-1064.
17. TUSCHL, T., and ECKSTEIN, F. (1993). Hammerhead ribozymes: importance of stem-loop II for activity. Proc. Natl. Acad. Sci. USA 90, 6991-6994.
18. VON LAER, D., HASSELMANN, S., and HASSELMANN, K. (2006). Gene therapy for HIV infection: what does it need to make it work? J. Gene Med. 8, 658-667.
19. WANG, L., WITHERINGTON, C., KING, A., GERLACH, W.L., CARR, A., PENNY, R., COOPER, D., SYMONDS, G., and SUN, L.Q. (1998). Preclinical characterization of an anti-tat ribozyme for therapeutic application. Hum. Gene Ther. 9, 1283-1291.
20. YAMADA, O., YU, M., YEE, J.K., KRAUS, G., LOONEY, D., and WONG-STAAL, F. (1994). Intracellular immunization of human T cells with a hairpin ribozyme against human immunodef-ciency virus type 1. Gene Ther. 1, 38-45.
21. YU, M., LEAVITT, M.C., MARUYAMA, M., YAMADA, O., YOUNG, D., HO, A.D., and WONG-STAAL, F. (1995a). Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodef ciency virus type 1. Proc. Natl. Acad. Sci. USA. 92, 699-703.
22. YU, M., POESCHLA, E., YAMADA, O., DEGRANDIS, P., LEAVITT, M.C., HEUSCH, M., YEES, J.K., WONG-STAAL, F., and HAMPEL, A. (1995b). In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1. Virology. 206, 381-386.
23. ZUKER, M. (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406-3415.